254 related articles for article (PubMed ID: 22275357)
1. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
[TBL] [Abstract][Full Text] [Related]
2. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
[TBL] [Abstract][Full Text] [Related]
3. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
4. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
[TBL] [Abstract][Full Text] [Related]
5. Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome.
Buysse K; Riemersma M; Powell G; van Reeuwijk J; Chitayat D; Roscioli T; Kamsteeg EJ; van den Elzen C; van Beusekom E; Blaser S; Babul-Hirji R; Halliday W; Wright GJ; Stemple DL; Lin YY; Lefeber DJ; van Bokhoven H
Hum Mol Genet; 2013 May; 22(9):1746-54. PubMed ID: 23359570
[TBL] [Abstract][Full Text] [Related]
6. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
[TBL] [Abstract][Full Text] [Related]
7. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
8. Expression and localization of fukutin, POMGnT1, and POMT1 in the central nervous system: consideration for functions of fukutin.
Yamamoto T; Kato Y; Kawaguchi M; Shibata N; Kobayashi M
Med Electron Microsc; 2004 Dec; 37(4):200-7. PubMed ID: 15614444
[TBL] [Abstract][Full Text] [Related]
9. [Current status and future prospects of research on Fukuyama muscular dystrophy].
Toda T
Nihon Rinsho; 2015 Aug; 73(8):1425-36. PubMed ID: 26281700
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
Taniguchi-Ikeda M; Kobayashi K; Kanagawa M; Yu CC; Mori K; Oda T; Kuga A; Kurahashi H; Akman HO; DiMauro S; Kaji R; Yokota T; Takeda S; Toda T
Nature; 2011 Oct; 478(7367):127-31. PubMed ID: 21979053
[TBL] [Abstract][Full Text] [Related]
11. Expression in retinal neurons of fukutin and FKRP, the protein products of two dystroglycanopathy-causative genes.
Haro C; Uribe ML; Quereda C; Cruces J; Martín-Nieto J
Mol Vis; 2018; 24():43-58. PubMed ID: 29416295
[TBL] [Abstract][Full Text] [Related]
12. Fukutin and alpha-dystroglycanopathies.
Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
[TBL] [Abstract][Full Text] [Related]
13. [Recent Advances in α-dystroglycanopathy].
Kuga A; Kanagawa M; Toda T
Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
[TBL] [Abstract][Full Text] [Related]
14. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
15. Pikachurin interaction with dystroglycan is diminished by defective O-mannosyl glycosylation in congenital muscular dystrophy models and rescued by LARGE overexpression.
Hu H; Li J; Zhang Z; Yu M
Neurosci Lett; 2011 Feb; 489(1):10-5. PubMed ID: 21129441
[TBL] [Abstract][Full Text] [Related]
16. Functional requirements for fukutin-related protein in the Golgi apparatus.
Esapa CT; Benson MA; Schröder JE; Martin-Rendon E; Brockington M; Brown SC; Muntoni F; Kröger S; Blake DJ
Hum Mol Genet; 2002 Dec; 11(26):3319-31. PubMed ID: 12471058
[TBL] [Abstract][Full Text] [Related]
17. Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan.
Kobayashi K; Kato R; Kondo-Iida E; Taniguchi-Ikeda M; Osawa M; Saito K; Toda T
J Hum Genet; 2017 Nov; 62(11):945-948. PubMed ID: 28680109
[TBL] [Abstract][Full Text] [Related]
18. Defective glycosylation of α-dystroglycan contributes to podocyte flattening.
Kojima K; Nosaka H; Kishimoto Y; Nishiyama Y; Fukuda S; Shimada M; Kodaka K; Saito F; Matsumura K; Shimizu T; Toda T; Takeda S; Kawachi H; Uchida S
Kidney Int; 2011 Feb; 79(3):311-6. PubMed ID: 20944549
[TBL] [Abstract][Full Text] [Related]
19. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
[TBL] [Abstract][Full Text] [Related]
20. Biochemical correlation of activity of the α-dystroglycan-modifying glycosyltransferase POMGnT1 with mutations in muscle-eye-brain disease.
Voglmeir J; Kaloo S; Laurent N; Meloni MM; Bohlmann L; Wilson IB; Flitsch SL
Biochem J; 2011 Jun; 436(2):447-55. PubMed ID: 21361872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
